Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer × lorlatinib × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Recurrence 1 Neuroblastoma 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Glioma 1 Glioblastoma 1 Ganglioneuroblastoma 1 Diffuse Intrinsic Pontine Glioma 1 Astrocytoma 1 Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1 Advanced Non-Small Cell Lung Cancer 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05297890 2025-12-23

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

CStone Pharmaceuticals

Phase 2 Active not recruiting

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡